Grip Strength in Patients with Gastrointestinal Diseases

Ken Asaishi 1,‡, Masahiro Matsui 1,2, Hiroki Nishikawa 1,2, Masahiro Goto 1, Akira Asai 1, Kosuke Ushiro 1, Takeshi Ogura 1, Toshihisa Takeuchi 1, Shiro Nakamura 1, Kazuki Kakimoto 1, Takako Miyazaki 1,2, Shinya Fukunishi 1,2, Hideko Ohama 1, Keisuke Yokohama 1, Hitotaka Yasuoka 1 and Kazuhide Higuchi 1

Abstract: We sought to elucidate factors contributing to the grip strength (GS) decline in patients with gastrointestinal diseases (Ga-Ds, n = 602, 379 males, median age = 72 years). The GS decline in males and females was defined as <28 kg and <18 kg, respectively, following the current Asian guidelines. The median GS (male) was 28.8 kg, and GS decline (male) was found in 169 patients (44.6%). The median GS (female) was 17.5 kg, and GS decline (female) was found in 122 patients (54.7%). Advanced cancer was identified in 145 patients (21.4%). In terms of the univariate analysis of parameters of the GS decline, age (p < 0.0001), gender (p = 0.0181), body mass index (BMI, p = 0.0002), ECOG-PS (p < 0.0001), SARC-F score (p < 0.0001), total lymphocyte count (p < 0.0001), serum albumin value (p < 0.0001), C reactive protein (CRP) value (p < 0.0001), and estimated glomerular filtration rate were statistically significant. In terms of the multivariate analysis, age (p < 0.0001), BMI (p = 0.0223), hemoglobin value (p = 0.0186), serum albumin value (p = 0.0284), the SARC-F score (p = 0.0003), and CRP value (p < 0.0001) were independent parameters. In conclusion, the GS decline in patients with Ga-Ds is closely associated with not only the primary factor (i.e., aging) but also secondary factors such as inflammatory factors and nutritional factors.

Keywords: grip strength; gastrointestinal disease; aging; malnutrition; inflammation

1. Introduction

Skeletal muscle, besides controlling body movement, functions as a store of protein and has an essential role in glucose uptake and energy metabolism [1,2]. Sarcopenia is characterized by progressive skeletal muscle mass loss and decline in function, linking to physical frailty and survival [1–3]. Malnutritional status, inactivity, advanced cancer burden, and persistent inflammatory state often seen in gastrointestinal diseases (Ga-Ds) are common features for sarcopenia [1–10]. Loss of dietary intakes and worsening of nutritional condition can be also frequently encountered in patients with Ga-Ds [9], and sarcopenia in patients with Ga-Ds is associated with decreased quality of life (QOL) and adverse outcomes [9,11]. Ga-D is a typical disease that causes secondary sarcopenia owing to the disease burden itself [11].

In recent years, a lot of studies have presented that grip strength (GS) is related to the onset of disease and life expectancy [12–15]. The results of a study in the UK that examined the relationship between GS, disease onset, and mortality were reported [16]. The study included 502,293 people aged 40–69 years, classified into four categories based...
on the baseline GS, and examined the relationship between GS and overall survival, cardiovascular disease-related survival, respiratory disease-related survival, and cancer-related survival [16]. The results showed that for every 5 kg decrease in GS, overall mortality increased by 20%, cardiovascular disease mortality increased by 19%, respiratory disease mortality increased by 31%, cancer mortality increased by 17%, and this relationship was particularly strong among young people [16]. In addition, the incidence and mortality rates of cardiovascular diseases, respiratory diseases, and cancers were all higher in people with GS of less than 26 kg in men and less than 16 kg in women. In other words, lower GS was as likely an indicator of future disease development and mortality as higher blood pressure and obesity, which are well-accepted prognostic markers [16].

The progression of muscle strength decline is usually accompanied by various metabolic changes [8]. As far as we are aware, however, there have been few reports with regard to factors contributing to the GS decline in patients with Ga-Ds. These problems may deserve to be solved, which urged us to conduct the current cross-sectional analysis.

2. Patients and Methods

2.1. Patients

In our hospital, between October 2020 and October 2021, 602 Japanese Ga-D hospitalized patients with data for GS were identified. In our hospital, GS has been routinely tested in each patient on admission, and sarcopenia risk was assessed according to the SARC-F. SARC-F is recommended for active use as an initial screening method for sarcopenia in the current globally accepted guidelines [17,18]. SARC-F is taken from S for Strength, A for Assistance walking, R for Rising from chair, C for Climbing stairs, and F for Falls, and each is rated on a scale of 0 to 2, with the total score being calculated [19–22]. In the Asian guidelines for sarcopenia, the recommended reference value of the SARC-F score for the presence of sarcopenia is 4 [17]. As a rule, each inpatient was required to be included in the SARC-F questionnaire on admission. GS was tested according to the guidelines [8]. In brief, the average of the left and right GS was used. The GS decline in male and female was defined as <28 kg and <18 kg, respectively, following the international guidelines [17].

2.2. Study Procedure and Ethics

First, the relevance between the GS decline and baseline characteristics was investigated. Next, univariate and multivariate analyses of the GS decline were carried out. Finally, receiver operating characteristic curve (ROC) analysis of the GS decline was enforced. Advanced cancer was defined as stage III or far advanced cancer. The study was retrospective in design, approved by the relevant institutional ethics committee (approval number, 2021-122), and conducted in accordance with the Declaration of Helsinki. As this study was a retrospective observational study, patients’ consent was waived.

2.3. Statistics

For the comparison between two groups of continuous variables, the most appropriate choice between the Student’s t test and the Mann–Whitney U test was selected after confirmation of distribution. Continuous variables were presented as median (interquartile range, IQR) unless otherwise mentioned. In between-group comparisons of nominal variables, the Pearson χ² test was utilized. In the univariate analysis, effect size was also presented. Multivariate logistic regression analysis for the GS decline was also conducted to choose independent parameters considering significant parameters in the univariate analysis. ROC analysis for calculating the area under the ROC (AUC) was also done, and the reference value was set up as the point at which the sum of sensitivity and specificity is maximized. A p value less than 0.05 was the significant level in this study according to the JMP ver. 15 (SAS Institute Inc., Cary, NC, USA).
3. Results

3.1. Patient Baseline Features

Table 1 presents baseline features of all study subjects (n = 602, 379 males and 223 females, median (IQR) age = 72 (64–79) years). The median (IQR) GS in males was 28.8 (23.6–34.3) kg, and GS decline in males (i.e., <28 kg) was found in 169 patients (44.6%). The median (IQR) GS in females was 17.5 (13.9–20.5) kg, and GS decline in females (i.e., <18 kg) was found in 122 patients (54.7%). The median (IQR) body mass index (BMI) was 21.9 (19.6–24.4) kg/m² (missing data, n = 2). The median (IQR) ECOG-PS was 0 (0–1). ECOG-PS 0 was found in 399 patients (66.3%), 1 in 108 (17.9%), 2 in 40 (6.6%), 3 in 38 (6.3%) and 4 in 17 (2.8%). The median (IQR) SARC-F score was 0 (0–2). There were 345 cases (57.3%) with a SARC-F score of 0, 99 (16.4%) with a score of 1, 52 (8.6%) with a score of 2, 33 (5.5%) with a score of 3, and 73 (12.1%) with a score of ≥4. Upper gastrointestinal disease (U-GD) was seen in 149 patients (advanced cancer, 37 cases (24.8%)), lower gastrointestinal disease (L-GD) in 156 (advanced cancer, 28 cases (18.0%)), biliary and pancreatic disease (BP-D) in 209 (advanced cancer, 54 cases (25.8%)), and liver disease (L-D) in 88 (advanced cancer, 26 cases (29.6%)). Overall, advanced cancer was identified in 145 patients (24.1%). Other than advanced cancer, diseases seen in patients included early-stage cancer and benign diseases such as chronic inflammatory disease, benign tumor, and infectious disease.

| Variables                           | Number or Median (IQR) |
|-------------------------------------|------------------------|
| Age (years)                         | 72 (64–79)             |
| Gender, male/female                 | 379/223                |
| ECOG-PS                             | 0 (0–1)                |
| Grip strength (male, kg)            | 28.8 (23.6–34.3)       |
| Grip strength (female, kg)          | 17.5 (13.9–20.5)       |
| The SARC-F score                    | 0 (0–2)                |
| Body mass index (kg/m²)             | 21.9 (19.6–24.4)       |
| Advanced cancer, yes/no             | 145/457                |
| Hemoglobin (g/dL)                   | 12.5 (11.1–13.8)       |
| Platelet count (×10⁴/µL)            | 21.9 (16.6–27.7)       |
| Total lymphocyte count (/µL)        | 1330 (989–1822)        |
| ALT (IU/L)                          | 19 (13–32)             |
| eGFR (mL/min/1.73 m²)               | 67 (35–81)             |
| Serum albumin (g/dL)                | 3.8 (3.4–4.2)          |
| C reactive protein (mg/dL)          | 0.18 (0.05–0.95)       |

IQR, interquartile range; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate.

3.2. GS Decline and ECOG-PS and BMI

In patients with ECOG-PS 0 (n = 399), 1 (n = 108), and ≥2 (n = 95), the percentage of GS decline was 35.3% (141/399), 63.9% (69/108), 85.3% (81/95) (p < 0.0001 in ECOG-PS 0 vs. 1, p < 0.0001 in ECOG-PS 0 vs. ≥2, p = 0.0007 in ECOG-PS 1 vs. ≥2, and overall p < 0.0001) (Figure 1A).

BMI (kg/m²) was classified into three groups (BMI (kg/m²) < 18.5, 18.5 < BMI (kg/m²) < 25, and BMI (kg/m²) > 25) based on the current guidelines in the Japanese Society for the Study of Obesity (JASSO) [23]. In patients with BMI (kg/m²) < 18.5 (n = 96), 18.5 < BMI (kg/m²) < 25 (n = 386), BMI (kg/m²) > 25 (n = 118), the percentage of GS decline was 62.5% (60/96), 48.5% (187/386), 36.4% (43/118) (p = 0.0164 in BMI (kg/m²) < 18.5 vs. 18.5 < BMI (kg/m²) < 25, p = 0.0264 in 18.5 < BMI (kg/m²) < 25 vs. BMI (kg/m²) > 25, p = 0.0002 in BMI (kg/m²) < 18.5 vs. BMI (kg/m²) > 25, and overall p = 0.0007) (Figure 1B).
3.3. GS Decline and the SARC-F Score

The median (IQR) SARC-F score in patients with GS decline \((n = 291)\) and without GS decline \((n = 311)\) was 1 (0–3) and 0 (0–0) \((p < 0.0001, \text{Figure 2A})\). The percentage of patients with a SARC-F score \(\geq 4\) in patients with and without GS decline was 21.7\% (63/291) and 3.2\% (10/311) \((p < 0.0001, \text{Figure 2B})\).

3.4. GS Decline According to the Primary Origin of the Disease

The percentage of GS decline in patients with U-GD, L-GD, BP-D, and L-D was 53.7\% (80/149) in U-GD, 39.7\% (62/156) in L-GD, 49.3\% (103/209) in BP-D, and 52.3\% (46/88) in L-D \((p = 0.0737)\).

3.5. GS Decline and the SARC-F Score in Patients with and without Advanced Cancer

In patients with advanced cancer \((n = 145)\), the median (IQR) SARC-F score in patients with GS decline \((n = 74)\) and without GS decline \((n = 71)\) was 2 (1–4) and 0 (0–1) \((p < 0.0001, \text{Figure 3A})\). The percentage of patients with a SARC-F score \(\geq 4\) in patients with and without GS decline was 27.0\% (20/74) and 8.5\% (6/71) \((p = 0.0045, \text{Figure 3B})\).
In patients without advanced cancer (n = 457), the median (IQR) SARC-F score in patients with GS decline (n = 217) and without GS decline (n = 240) was 1 (0–3) and 0 (0–0) (p < 0.0001, Figure 3C). The percentage of patients with a SARC-F score ≥ 4 in patients with and without GS decline was 19.8% (43/217) and 1.7% (4/240) (p < 0.0001, Figure 3D).

3.6. GS Decline According to the Primary Disease Site in Patients with and without Advanced Cancer

Among four categories of primary origin in patients with advanced cancer, no significant difference was seen in the percentage of GS decline (62.2% (23/37) in U-GD, 32.1% (5/16) in L-GD, 47.7% (74/155) in BP-D, 53.2% (33/62) in L-D, overall p = 0.1117).

Among four categories of primary origin in patients without advanced cancer, no significant difference was seen in the percentage of GS decline (50.9% (57/112) in U-GD, 47.7% (74/155) in BP-D, 53.2% (33/62) in L-D, overall p = 0.3558).

3.7. Uni- and Multivariate Analysis of Variables for the GS Decline

In the univariate analysis of variables for the GS decline, age (p < 0.0001), gender (p = 0.0181), BMI (p = 0.0002), ECOG-PS (p < 0.0001), SARC-F score (p < 0.0001), hemoglobin value (p < 0.0001), total lymphocyte count (p < 0.0001), serum albumin value (p < 0.0001), C reactive protein (CRP) value (p < 0.0001), and estimated glomerular filtration rate were statistically significant (Table 2). In the multivariate analysis, age (p < 0.0001), BMI (p = 0.0223), hemoglobin value (p = 0.0186), serum albumin value (p = 0.0284), the SARC-F score
(p = 0.0003), and CRP value (p < 0.0001) were independent parameters of the GS decline (Table 3). Table 3 involves hazard ratio and 95% confidence interval in each factor.

Table 2. Univariate analysis of factors associated with the grip strength decline.

| Variables                  | Grip Strength Decline (n = 291) | Grip Strength Non-Decline (n = 311) | p Value | Effect Size |
|----------------------------|---------------------------------|-------------------------------------|---------|-------------|
| Age (years)                | 77 (71–82)                      | 68 (56–74)                          | <0.0001 | 0.15        |
| Gender (male/female)       | 169/122                         | 210/101                             | 0.0181  | 0.10        |
| BMI (kg/m²)                | 21.1 (19.0–23.9)                | 22.7 (20.1–24.9)                    | 0.0002  | 0.15        |
| ECOG-PS                    | 1 (0–2)                         | 0 (0–0)                             | <0.0001 | 0.36        |
| Advanced cancer, yes/no    | 74/217                          | 71/240                              | 0.5045  | 0.03        |
| Primary origin of disease  | U-GD/L-GD/BP-D/L-D               | 80/62/103/46                        | 0.0737  | 0.11        |
| SARC-F score               | 1 (0–3)                         | 0 (0–0)                             | <0.0001 | 0.38        |
| Hemoglobin (g/dL)          | 11.7 (10.6–13.1)                | 13.2 (11.8–14.3)                    | <0.0001 | 0.33        |
| Platelet count (×10⁴/µL)   | 21.4 (15.8–28.0)                | 22.4 (17.6–27.5)                    | 0.4667  | 0.0          |
| Total lymphocyte count (/µL)| 1251 (900–1728)                 | 1480 (1092–1890)                    | <0.0001 | 0.16        |
| Serum albumin (g/dL)       | 3.6 (3.1–4.0)                   | 4.0 (3.7–4.3)                       | <0.0001 | 0.32        |
| CRP (mg/dL)                | 0.30 (0.07–2.32)                | 0.13 (0.05–0.41)                    | <0.0001 | 0.19        |
| ALT (IU/L)                 | 19 (12–32)                      | 19 (13–32)                          | 0.7145  | 0.01        |
| eGFR (mL/min/1.73 m²)      | 63 (51–79)                      | 71 (58–82)                          | 0.0003  | 0.15        |

Data are expressed as number or median value (interquartile range). BMI, body mass index; U-GD, upper gastrointestinal disease; L-GD, lower gastrointestinal disease; BP-D, biliary pancreatic disease; L-D, liver disease; CRP, C reactive protein; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate.

Table 3. Multivariate analysis of factors for the grip strength decline.

| Variables                  | Multivariate Analysis | p Value |
|----------------------------|-----------------------|---------|
| Age (per one year)         | 1.052                 | <0.0001 |
| BMI (per one kg/m²)        | 0.938                 | 0.0223  |
| ECOG-PS (per one)          | 1.221                 | 0.2678  |
| Gender (female)            | 1.294                 | 0.2268  |
| SARC-F score (per one)     | 1.467                 | 0.0003  |
| Hemoglobin (per one g/dL)  | 0.863                 | 0.0186  |
| Serum albumin (per one g/dL) | 0.622             | 0.0284  |
| Total lymphocyte count (per one/µL) | 0.9999 | 0.4603  |
| eGFR (per one mL/min/1.73 m²) | 0.996              | 0.4349  |
| CRP (per one mg/dL)        | 1.069                 | 0.0331  |

BMI: body mass index; eGFR: estimated glomerular filtration rate; CRP: C reactive protein; HR: hazard ratio; CI: confidence interval.

3.8. ROC Analysis of Independent Parameters for the GS Decline

ROC analysis of independent factors in the multivariate analysis for GS decline was performed. AUC, the sensitivity, the specificity, and optimal reference value in each factor are demonstrated in Table 4. Age had the highest AUC for the GS decline (AUC = 0.74), followed by the SARC-F score (AUC = 0.73). The optimal reference value of the SARC-F score was 1, but when the reference value of the SARC-F score was changed to 4 (recommended reference value in the Asian guidelines), the sensitivity and specificity was 21.7% and 96.8%.
Table 4. Receiver operating characteristic curve analysis of independent factors in the multivariate analysis for the grip strength decline.

| Variables       | AUC  | Sensitivity (%) | Specificity (%) | Reference Value |
|-----------------|------|-----------------|-----------------|-----------------|
| Age (years)     | 0.74 | 72.9            | 65.0            | 72              |
| BMI (kg/m²)     | 0.60 | 68.3            | 51.3            | 22.6            |
| SARC-F score    | 0.73 | 64.3            | 77.5            | 1               |
| Hemoglobin (g/dL)| 0.70 | 65.6            | 66.2            | 12.4            |
| Serum albumin (g/dL) | 0.70 | 80.8            | 49.8            | 4.0             |
| CRP (mg/dL)     | 0.60 | 44.0            | 76.5            | 0.46            |

BMI, body mass index; CRP, C reactive protein; AUC, area under the receiver operating characteristic curve.

4. Discussion

Skeletal muscle mass and strength decrease from middle age to old age. Research related to sarcopenia has been progressing rapidly around the world in recent years. New evidence is also emerging on drug interventions for sarcopenia [24,25]. While in the COVID-19 pandemic, muscle strength decline is a serious concern due to decreased physical activity in daily life [26]. Many studies have shown that GS is related to the overall strength of the whole body, and GS decline is associated with decreased physical activity and adverse prognosis [12–15,27]. In our previous study, decreased GS was an independent adverse predictor for overall survival in patients with chronic liver disease (n = 1624) [27]. However, to our knowledge, few reports have addressed the contributing factors for GS decline in patients with Ga-Ds. To clarify these issues appears to be clinically meaningful. A large cohort (n = 602) is a major strength in the current analysis.

In our results, older age, lower BMI, lower hemoglobin, lower serum albumin, higher SARC-F score, and higher CRP level were independent factors for the GS decline in our multivariate analysis. These results imply that the GS decline in Ga-Ds is closely associated with not only the primary factor (i.e., aging) but also secondary factors such as inflammatory factor and nutritional factor. SARC-F involves strength (S, “How difficult is it to lift or carry an object weighing around 4.5 kg?”) [19,20], and thus it is not so surprising that the SARC-F score was an independent parameter of the GS decline. Advanced cancer and primary site of disease were not independent factors for the GS decline. The location of the primary lesion and the degree of disease progression do not seem to be directly related to the GS decline.

In our data, the median GS in males and females was 28.8 kg and 17.5 kg, which was considerably lower than that in Japanese people aged >60 years (average GS: male, 38.8 kg; female, 24.2 kg [28]). Multiple factors related to the GS decline in Ga-Ds may account for the current results. On the other hand, out of patients with the GS decline (n = 291), the average SARC-F score in patients with BMI (kg/m²) < 18.5 (n = 60), 18.5 < BMI (kg/m²) < 25 (n = 187), and BMI (kg/m²) > 25 (n = 43) was 1.7, 1.9 and 2.1, respectively. These results indicated that patients with the GS decline and BMI > 25 kg/m² had the highest possibility for the definite diagnosis of sarcopenia. Sarcopenic obesity may be a serious concern in clinical settings because of its prognostic impact [29–31]. For Japanese people, a BMI of 22 kg/m² is said to be the least likely to cause illness [32]. In our ROC analysis of BMI for the GS decline, the optimal reference value of BMI was 22.6 kg/m², which is almost identical to the previous reports [32].

CRP value was an independent predictor for the GS decline. A recent meta-analysis reported that independent of disease state, higher CRP values were associated with GS decrease and knee extension strength decrease, which is in line with our data [33]. Proinflammatory cytokines such as TNF-α, IL-1β, IL-6, IFN-γ, and chemokines can cause increment in energy expenditure, appetite loss, and reduced dietary intake, which can be also linked to the current results [27]. Appropriate nutritional interventions may be considered for patients with higher CRP values [34]. Cachexia is common in patients with diseases related to chronic inflammation and skeletal muscle mass loss [35]. Although cachexia is common in patients with Ga-Ds, it is not well recognized by medical experts, and in most cases, the nutritional status deteriorates further without being diagnosed, resulting in
skeletal muscle mass loss and decreased physical function [36,37]. In terms of SARC-F, the optimal reference value of the SARC-F score was 1 (the sensitivity/specificity, 64.3/77.5%), but when the reference value of the SARC-F score was changed to 4 (recommended reference value in the Asian guidelines [17]), the sensitivity/specificity was 21.7/96.8%. The relatively low sensitivity of the SARC-F score to the diagnosis of sarcopenia is a concern, which is identical to the current results [38–40]. The recommended reference value of the SARC-F score may be re-considered. On the other hand, lower hemoglobin value was independently linked to the GS decline in our data. A Korean study demonstrated a strong association between lower GS and anemia, which is in line with our data [41].

It should be understood that there are several limitations to the present analysis. First, this study is a single-center, cross-sectional study and is retrospective in nature. Second, because data for skeletal muscle mass was not available in the current analysis, the exact number of subjects with a confirmed diagnosis for sarcopenia was unknown. Third, the cohort in this study was highly heterogeneous, including a wide range of Ga-Ds (i.e., U-GD, L-GD, BP-D, and L-D). Fourth, patient daily activities or dietary habits, which can affect GS, were not analyzed in this study, also creating bias. Fifth, effect size was relatively small throughout analyzed parameters. Nevertheless, our study results denoted that GS can be influenced by various factors other than aging in patients with GDs. In conclusion, we would like to emphasize this as an important point when considering the GS decline in patients with Ga-Ds.

**Author Contributions:** Data curation, K.A., M.M., H.N., M.G., A.A., T.O., T.T., S.N., K.K., T.M., S.F., K.Y. and H.Y.; Formal analysis, H.N., K.U. and H.O.; Supervision, M.G. and K.H.; Writing—original draft, K.A. and H.N.; Writing—review & editing, H.N. and K.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Osaka medical and pharmaceutical university (Approval number, 2021-122: date of approval, 10 January 2022).

**Informed Consent Statement:** Patient consent was waived due to the retrospective study design.

**Data Availability Statement:** The data are not publicly available due to personal information of our study cohort.

**Acknowledgments:** The authors gratefully thank all medical staff in our department for their help with data collection.

**Conflicts of Interest:** None of the authors has any conflict of interest to declare.

**Abbreviations**

- Ga-D: gastrointestinal disease,
- QOL: quality of life,
- GS: grip strength,
- BMI: body mass index,
- ROC: receiver operating characteristic curve,
- IQR: interquartile range,
- AUC: area under the receiver operating characteristic curve,
- U-GD: upper gastrointestinal disease,
- L-GD: lower gastrointestinal disease,
- BP-D: biliary and pancreatic disease,
- L-D: liver disease,
- CRP: C reactive protein.

**References**

1. Nishikawa, H.; Fukunishi, S.; Asai, A.; Yokohama, K.; Nishiguchi, S.; Higuchi, K. Pathophysiology and mechanisms of primary sarcopenia. *Int. J. Mol. Med.* 2021, 48, 156. [CrossRef] [PubMed]
2. Ganapathy, A.; Nieves, J.W. Nutrition and Sarcopenia—What Do We Know? *Nutrients* 2020, 12, 1755. [CrossRef]
3. Raquel, L.R.; Vicente, R.P.; José, L.G.S.; Anxela, S.R. Prevalence and Factors Associated with Functional Limitations during Aging in a Representative Sample of Spanish Population. *Phys. Occup. Ther. Geriatr.* 2018, 36, 156–167.
4. Chhetri, J.K.; de Souto Barreto, P.; Fougère, B.; Rolland, Y.; Vellas, B.; Cesari, M. Chronic inflammation and sarcopenia: A regenerative cell therapy perspective. *Exp. Gerontol.* 2018, 103, 115–123. [CrossRef] [PubMed]
5. Sieber, C.C. Malnutrition and sarcopenia. *Aging Clin. Exp. Res.* 2019, 31, 793–798. [CrossRef]
6. Shaw, C. Management of diet in gastrointestinal cancer. *Proc. Nutr. Soc.* 2021, 80, 65–72. [CrossRef]
7. Balestrieri, P.; Ribolzi, M.; Guarino, M.P.L.; Emerenziani, S.; Altemore, A.; Cicala, M. Nutritional Aspects in Inflammatory Bowel Diseases. *Nutrients* **2020**, *12*, 372. [CrossRef]

8. Nishikawa, H.; Shiraki, M.; Hiramatsu, A.; Moriya, K.; Hino, K.; Nishiguchi, S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. *Hepatol. Res.* **2016**, *46*, 951–963. [CrossRef]

9. Dunne, R.F.; Loh, K.P.; Williams, G.R.; Jatoi, A.; Mustian, K.M.; Mohile, S.G. Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review. *Cancers* **2019**, *11*, 1861. [CrossRef]

10. Wang, H.; Yang, R.; Xu, J.; Fang, K.; Abdelrahim, M.; Chang, L. Sarcopenia as a predictor of postoperative risk of complications, mortality and length of stay following gastrointestinal oncological surgery. *Ann. R. Coll. Surg. Engl.* **2021**, *103*, 630–637. [CrossRef]

11. Meyer, F.; Valentini, L. Disease-Related Malnutrition and Sarcopenia as Determinants of Clinical Outcome. *Visc. Med.* **2019**, *35*, 282–291. [CrossRef] [PubMed]

12. Bohannon, R.W. Grip Strength: An Indispensable Biomarker For Older Adults. *Clin. Interv. Aging* **2019**, *14*, 1681–1691. [CrossRef] [PubMed]

13. Nakano, J.; Fukushima, T.; Tanaka, T.; Fu, J.B.; Morishita, S. Physical function predicts mortality in patients with cancer: A systematic review and meta-analysis of observational studies. *Support Care Cancer* **2021**, *29*, 5623–5634. [CrossRef] [PubMed]

14. Hollingsworth, T.W.; Oke, S.M.; Patel, H.; Smith, T.R. Getting to grips with sarcopenia: Recent advances and practical management for the gastroenterologist. *Frontline Gastroenterol.* **2020**, *12*, 53–61. [CrossRef]

15. Leong, D.P.; Teo, K.K.; Rangarajan, S.; Lopez-Jaramillo, P.; Avezum, A., Jr.; Orlandini, A.; Seron, P.; Ahmed, S.H.; Rosengren, A.; Kelishadi, R.; et al. Prospective Urban Rural Epidemiology (PURE) Study investigators. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet* **2015**, *386*, 266–273. [CrossRef]

16. Celis-Morales, C.A.; Welsh, P.; Lyall, D.M.; Steell, L.; Petermann, F.; Anderson, J.; Ilidromiti, S.; Sillars, A.; Graham, N.; Mackay, D.F.; et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all-cause mortality: Prospective cohort study of half a million UK Biobank participants. *BMJ* **2018**, *361*, k1651.

17. Chen, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Chou, M.Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J. Am. Med. Dir. Assoc.* **2020**, *21*, 300–307.e2. [CrossRef]

18. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Rocker, G.; et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J. Am. Med. Dir. Assoc.* **2019**, *20*, 1874–1885. [CrossRef] [PubMed]

19. Nakano, J.; Kouchi, T.; Tanaka, T.; Fu, J.B.; Morishita, S. Physical function predicts mortality in patients with cancer: A systematic review and meta-analysis of observational studies. *Support Care Cancer* **2021**, *29*, 5623–5634. [CrossRef] [PubMed]

20. Hanai, T.; Shiraki, M.; Imai, K.; Suetugu, A.; Takai, K.; Shimizu, M. Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. *Nutrients* **2021**, *13*, 1874. [CrossRef]

21. Hanai, T.; Shiraki, M.; Imai, K.; Suetugu, A.; Takai, K.; Shimizu, M. Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. *Nutrients* **2020**, *12*, 1915. [CrossRef] [PubMed]

22. Tuzun, S.; Keles, A.; Okutan, D.; Yildiran, T.; Palamar, D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. *Eur. J. Phys. Rehabil. Med.* **2021**, *57*, 653–662. [CrossRef] [PubMed]

23. Nakano, J.; Kouchi, T.; Tanaka, T.; Fu, J.B.; Morishita, S. Physical function predicts mortality in patients with cancer: A systematic review and meta-analysis of observational studies. *Support Care Cancer* **2021**, *29*, 5623–5634. [CrossRef] [PubMed]

24. Okubo, T.; Atsukawa, M.; Tsubota, A.; Ono, H.; Kawano, T.; Yoshida, Y.; Arai, T.; Hayama, K.; Itokawa, N.; Kondo, C.; et al. Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis. *Nutrients* **2021**, *13*, 372. [CrossRef] [PubMed]

25. Hanai, T.; Shiraki, M.; Hiramatsu, A.; Moriya, K.; Hino, K.; Nishiguchi, S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. *Hepatol. Res.* **2016**, *46*, 951–963. [CrossRef]

26. Hanai, T.; Shiraki, M.; Imai, K.; Suetugu, A.; Takai, K.; Shimizu, M. Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. *Nutrients* **2021**, *13*, 1874. [CrossRef]

27. Colleluori, G.; Villarel, D.T. Aging, obesity, sarcopenia and the effect of diet and exercise intervention. *Exp. Gerontol.* **2021**, *155*, 111561. [CrossRef]

28. Hsu, K.J.; Liao, C.D.; Tsai, M.W.; Chen, C.N. Effects of Exercise and Nutritional Intervention on Body Composition, Metabolic Health, and Physical Performance in Adults with Sarcopenic Obesity: A Meta-Analysis. *Nutrients* **2019**, *11*, 2163. [CrossRef]

29. Tokunaga, K.; Matsuzawa, Y.; Kotani, K.; Keno, Y.; Kobatake, T.; Fujikawa, S.; Harai, S. Ideal body weight estimated from the body mass index with the lowest morbidity. *Int. J. Obes.* **1991**, *15*, 1–5.
33. Tuttle, C.S.L.; Thang, L.A.N.; Maier, A.B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. *Ageing Res. Rev.* **2020**, *64*, 101185. [CrossRef] [PubMed]
34. Wakabayashi, H.; Arai, H.; Inui, A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: Facts and numbers. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 14–16. [CrossRef] [PubMed]
35. Nishikawa, H.; Goto, M.; Fukumishi, S.; Asai, A.; Nishiguchi, S.; Higuchi, K. Cancer Cachexia: Its Mechanism and Clinical Significance. *Int. J. Mol. Sci.* **2021**, *22*, 8491. [CrossRef] [PubMed]
36. Bielecka-Dabrowa, A.; Ebner, N.; Dos Santos, M.R.; Ishida, J.; Hasenfuss, G.; von Haehling, S. Cachexia, muscle wasting, and frailty in cardiovascular disease. *Eur. J. Heart Fail.* **2020**, *22*, 2314–2326. [CrossRef]
37. Wyart, E.; Bindels, L.B.; Mina, E.; Menga, A.; Stanga, S.; Porporato, P.E. Cachexia, a Systemic Disease beyond Muscle Atrophy. *Int. J. Mol. Sci.* **2020**, *21*, 8592. [CrossRef] [PubMed]
38. Voelker, S.N.; Michalopoulos, N.; Maier, A.B.; Reijnierse, E.M. Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis. *J. Am. Med. Dir. Assoc.* **2021**, *22*, 1864–1876. [CrossRef]
39. Kurita, N.; Wakita, T.; Kamitani, T.; Wada, O.; Mizuno, K. SARC-F Validation and SARC-F+EBM Derivation in Musculoskeletal Disease: The SPSS-OK Study. *J. Nutr. Health Aging* **2019**, *23*, 732–738. [CrossRef]
40. Barbosa-Silva, T.G.; Menezes, A.M.; Bielemann, R.M.; Malmstrom, T.K.; Gonzalez, M.C.; Grupo de Estudos em Composição Corporal e Nutrição (COCONUT). Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 1136–1141. [CrossRef]
41. Gi, Y.M.; Jung, B.; Kim, K.W.; Cho, J.H.; Ha, I.H. Low handgrip strength is closely associated with anemia among adults: A cross-sectional study using Korea National Health and Nutrition Examination Survey (KNHANES). *PLoS ONE* **2020**, *15*, e0218058. [CrossRef]